IDENTIFICATION OF MUSCLE-SPECIFIC BIOMARKERS OF BETA-OXIDATION
Project Number: 5306-51530-019-16
General Cooperative Agreement
Start Date: Aug 04, 2009
End Date: Jul 31, 2013
Elevated fat levels within skeletal muscle cells (intramyocellular lipids) are highly correlated with muscle and whole-body insulin resistance, and more prevalent in obesity. The molecular links and metabolic shifts driving this association remain open to debate, but notably, reduced muscle mitochondrial fatty acid (FA) beta-oxidation is more prevalent among insulin-resistant/diabetic persons. Therefore, discovery of biomarkers reflective of the status of an individual’s muscle FA beta-oxidation activity or capacity would have tremendous prognostic and diagnostic value in terms of diabetes. Furthermore, characterization of metabolites associated with muscle mitochondrial fat metabolism should uncover candidate signaling factors which tie FA ß-oxidation to insulin signaling. We propose to identify, for the first time, specific biomarkers of muscle FA beta-oxidation using multiple metabolomic analytical platforms to compare metabolite profiles in samples derived from biological systems displaying disparate muscle fat combustion, including: isolated mitochondrial organelles and muscle cells catabolizing FA at different rates, a UCP3 transgenic animal model, and human subjects harboring a UCP3 truncation polymorphism. Pilot validation studies will test whether plasma metabolites and/or metabolite signatures identified in cell, animal, and human studies that track muscular FA beta-oxidation can be experimentally increased in obese, insulin-resistant subjects via a diet-exercise regimen designed to improve muscle fitness and FA combustion.
Identify Metabolite Biomarkers of Muscle Fat Combustion in Humans Harboring a UCP3 Missense Polymorphic Allele. We predict that subjects with this uncoupling protein 3 (UCP3) polymorphism (that yields a truncated UCP3 and 50% decreased whole-body fat combustion) will display a distinctive plasma metabolite profile indicative of reduced muscle FA oxidation, when compared to subjects without the polymorphism. This will be evaluated by obtaining blood plasma from individuals with or without the polymorphism, at rest and after a brief exercise bout.
Documents Grant with U of Alabama. Formerly 5306-51530-016-11G (8/26/09)